Company research
Oaktree Acquisition Corp. III Life Sciences
CIK 2029769Updated Sep 27, 2026
OACC price & chart
Loading TradingView…
NASDAQ:OACC on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
PRE 14A filing
SCHEDULE 13G filing
10-Q filing
SCHEDULE 13G - filed by Fort Baker Capital Management LP regarding Oaktree Acquisition Corp. III Life Sciences
10-Q filing
Show 5 more recent filings
10-K filing
10-Q filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
3 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| ASSETS | ||
| AssetsUSD | 203,111,772Source | 195,250,622Source |
| Current assets: | ||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,434,965Source | 1,357,044Source |
| Assets, CurrentUSD | 1,548,240Source | 1,558,325Source |
| LIABILITIES AND EQUITY | ||
| LiabilitiesUSD | 8,318,397Source | 7,746,071Source |
| Stockholders’ equity: | ||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source |
| Additional Paid in CapitalUSD | 0Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -6,770,695Source | -6,075,009Source |
| Stockholders' Equity Attributable to ParentUSD | -6,770,157Source | -6,074,471Source |
| Liabilities and EquityUSD | 203,111,772Source | 195,250,622Source |
| Current liabilities: | ||
| Liabilities, CurrentUSD | 1,299,649Source | 727,323Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -422,079Source | — |
| Cash flows from investing activities: | ||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 500,000Source | — |
| Cash flows from financing activities: | ||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 0Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,434,965Source | 1,357,044Source |
| Additional Financial Items | ||
| Investment Income, InterestUSD | 8,484,511Source | — |
| Net Income (Loss) Attributable to ParentUSD | 7,288,824Source | — |
| Nonoperating Income (Expense)USD | 8,484,511Source | — |
| Operating Costs and ExpensesUSD | 1,195,687Source | — |
income statement · annual statements
| Line item | FY 2025 |
|---|---|
| Operating Income (Loss)USD | -1,195,687Source |
| Net Income (Loss) Attributable to ParentUSD | 7,288,824Source |
| Additional Financial Items | |
| Investment Income, InterestUSD | 8,484,511Source |
| Nonoperating Income (Expense)USD | 8,484,511Source |
| Operating Costs and ExpensesUSD | 1,195,687Source |